Pay in 4 interest-free payments of $5.16 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice
Awesome service
By Use Case Stubborn Fat Reduction Timeline: 6-12 weeks for visible changes Best approach: 300mcg fasted, consistent caloric deficit, fasted cardio Realistic expectation: 4-8 lbs additional fat loss over 12 weeks vs diet alone Body Recomposition (Stacked) Timeline: 4-8 weeks for synergistic effects Common stacks: AOD-9604 + CJC-1295/Ipamorelin for GH-enhanced fat loss, or AOD-9604 + low-dose semaglutide for appetite control + enhanced fat oxidation Realistic expectation: Faster results than AOD-9604 alone, but more variables to manage Post-GLP-1 Transition Timeline: Begin immediately after tapering off semaglutide or tirzepatide Purpose: Maintain fat oxidation support while transitioning away from appetite-suppressing peptides Realistic expectation: May help prevent rebound weight gain by sustaining lipolytic activity, though this is community-reported, not clinically studied When to Adjust Protocol Signs it's working: Gradual but consistent downward trend in waist measurement Clothes fitting differently even if scale weight is stable Improved fasted cardio endurance Better body composition in progress photos at 6+ weeks Signs to reassess: Zero measurable change by week 8 with optimized timing and deficit No subjective difference in energy or body composition Side effects (rare but worth noting: headache, nausea) If it's not working: Verify fasted injection timing (no food 1-2 hours before or after) Confirm caloric deficit (track intake for 2 weeks) Consider increasing to 500mcg/day Evaluate whether a different mechanism (GLP-1, GH secretagogue) would be more appropriate for the goal Research Supplies for AOD-9604 Hand-picked storage, injection, and recovery supplies paired with AOD-9604 protocols
And even if you feel totally fine, its still smart to get a quick check-up or blood test first
AOD-9604 administers subcutaneously, meaning into the fat layer just beneath the skin
